| Style | Citing Format |
|---|---|
| MLA | Kermani F, et al.. "Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy." Translational Oncology, vol. 20, no. , 2022, pp. -. |
| APA | Kermani F, Vojdanisaghir A, Mollazadeh Beidokhti S, Nazarnezhad S, Mollaei Z, Hamzehlou S, Elfiqi A, Baino F, Kargozar S (2022). Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy. Translational Oncology, 20(), -. |
| Chicago | Kermani F, Vojdanisaghir A, Mollazadeh Beidokhti S, Nazarnezhad S, Mollaei Z, Hamzehlou S, Elfiqi A, Baino F, Kargozar S. "Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy." Translational Oncology 20, no. (2022): -. |
| Harvard | Kermani F et al. (2022) 'Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy', Translational Oncology, 20(), pp. -. |
| Vancouver | Kermani F, Vojdanisaghir A, Mollazadeh Beidokhti S, Nazarnezhad S, Mollaei Z, Hamzehlou S, et al.. Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy. Translational Oncology. 2022;20():-. |
| BibTex | @article{ author = {Kermani F and Vojdanisaghir A and Mollazadeh Beidokhti S and Nazarnezhad S and Mollaei Z and Hamzehlou S and Elfiqi A and Baino F and Kargozar S}, title = {Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy}, journal = {Translational Oncology}, volume = {20}, number = {}, pages = {-}, year = {2022} } |
| RIS | TY - JOUR AU - Kermani F AU - Vojdanisaghir A AU - Mollazadeh Beidokhti S AU - Nazarnezhad S AU - Mollaei Z AU - Hamzehlou S AU - Elfiqi A AU - Baino F AU - Kargozar S TI - Iron (Fe)-Doped Mesoporous 45S5 Bioactive Glasses: Implications for Cancer Therapy JO - Translational Oncology VL - 20 IS - SP - EP - PY - 2022 ER - |